



Katherine E. Reeder-Hayes, M.D., MBA, MSCR

“Thanks to prior research, we now know there is a big gap between the ideal, where patients take their breast cancer endocrine therapy pills every day for five or more years, and the real world, where patients may experience various challenges as they try to stick to their treatment plans on a daily basis. These medications are not easy to take. Yet, we know that endocrine therapy saves lives, and we hope our research can help all breast cancer survivors take full advantage of that lifesaving treatment by supporting survivor medication adherence, taking their medication for as long as they need it.”

-Katherine E. Reeder-Hayes, M.D., MBA, MSCR



Stephanie Wheeler, Ph.D., MPH



KOMEN.ORG
1-877-GO KOMEN

Hormone Therapy Medication Adherence Study

STUDY TITLE: Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormone Therapy

TRIAL NUMBER: NCT04379570

FOCUS: Adherence

TRIAL PHASE: [Phase III \(Phase 3\)](#)

WHAT HAPPENS IN THIS STUDY?

The goal of this study, also referred to as the Guiding Endocrine Therapy Success through Empowerment & Technology (GET SET) Study, is to test whether an additional support program including text message reminders and/or telephone-based counseling will increase the number of days patients take their [hormone therapy](#) (endocrine therapy) [medication as prescribed](#). This support program will be compared to the usual standard of care received by patients during regular clinic visits.

This is a randomized trial, which means neither the doctor nor the participant choose the study group for a patient. Instead, participants are assigned to a study group by chance. Every participant will receive online educational information. In addition, participants will also be randomly assigned to one of the following groups: 1) text messages, 2) motivational interviewing counseling sessions via telephone, 3) text messages and motivational interviewing counseling sessions via telephone, or 4) the standard of care clinic visits.

ARE YOU ELIGIBLE?

A woman over the age of 18 may be eligible if she has been diagnosed with stage I-III hormone-positive, HER2-negative invasive breast cancer within the last 18 months and has undergone neoadjuvant chemotherapy with no residual invasive disease after surgery and no prior history of breast cancer.

The status of this study is subject to change. To see the most current information, visit clinicaltrials.gov.

WHAT WILL THIS MEAN FOR PATIENTS?

This study offers participants the chance to receive different types of support to aid in following their [treatment plan](#). It will help researchers and doctors learn which support programs work better to remind patients to follow their treatment plan. Participants will be contributing to cancer research that one day may help to improve the treatment and outcomes of hormone-positive breast cancer for others.

WHO DO I CONTACT ABOUT THIS STUDY?

LEAD TRIAL PIS:

- Katherine E. Reeder-Hayes, M.D., MBA, MSCR, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.
- Stephanie Wheeler, Ph.D., MPH, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States.

STUDY LOCATIONS:

This study is offered at multiple sites across the country. See if there is a [research site](#) near you or get [contact information](#) for a study location.

KOMEN CONNECTION

Katherine E. Reeder-Hayes, M.D., MBA, MSCR, a Principal Investigator (PI) of this study, is a former Komen grantee from the University of North Carolina Lineberger Comprehensive Cancer Center and a current contributor to the Komen-funded Carolina Breast Cancer Study. She is a leading expert on health disparities in breast cancer, and her research interests include patient data resources, qualitative and survey studies, and behavioral interventions for breast cancer patients.

SUSAN G. KOMEN BREAST CARE HELPLINE

For more information about clinical trials, please call our Breast Care Helpline at 1-877 GO KOMEN (1-877-465-6636) or email at clinicaltrialinfo@komen.org to connect with a trained specialist. Our caring and trained staff provide support and education about clinical trials to help people gain a better understanding of clinical trials.

Disclaimer

This information is being provided for education purposes only and does not contain all information related to this clinical study. The study status and eligibility criteria may change. If you are interested in learning if this study is right for you, please reach out to the study coordinator or your doctor for more information.